EUVIMEDEUVIMED entdecken
Fallbericht

Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis

Tanvi Vaidya, Monisha Madhumita iD

International Journal of STD & AIDS · 2025

DOI: 10.1177/09564624251315781 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of STD & AIDS, 2025. Verfasst von Tanvi Vaidya und 1 weiteren Autor:innen. Beteiligte Einrichtung: Derma MD Clinics, Mumbai, India. Hauptthemen laut MEDLINE: Alopecia Areata, Hair, Hirsutism, HIV Infections. Die Arbeit nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tofacitinib is a Janus kinase 3 (JAK3) inhibitor effective in treating alopecia areata (AA) by promoting hair regrowth. Its mechanism may involve upregulation of vascular endothelial growth factor (VEGF) and reduction of inflammation. However, the range of effects, particularly on hair growth in specific populations, remains under-investigated. We describe a patient with HIV, well-controlled on antiretroviral therapy, who developed hirsutism after starting tofacitinib for AA. This unexpected side effect of hypertrichosis was completely resolved after discontinuing the medication and undergoing a single session of laser hair removal (LHR). This case highlights the potential for unusual hair growth patterns associated with tofacitinib treatment in patients with immune dysregulation. Monitoring and management strategies for such side effects are discussed. This case highlights the potential for unusual hair growth patterns associated with tofacitinib treatment in patients with immune dysregulation. Monitoring and management strategies for such side effects are discussed. The case emphasizes the need for careful monitoring of hair growth and other potential side effects in patients on tofacitinib, especially those with underlying immune-modulating conditions. It also suggests that LHR can be an effective treatment for medication-induced hirsutism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataHairHirsutismHIV InfectionsHypertrichosisPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolesHumansHair RemovalImmunomodulationTreatment Outcome

Stichwörter der Autor:innen

HIVTofacitinibalopecia areataantiretroviral therapyhirsutismhypertrichosisjanus kinase inhibitorlaser hair removalvascular endothelial growth factor

Substanzen

PiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolestofacitinib

Autor:innen und Institutionen

  • Derma MD Clinics, Mumbai, India.
  • Department of Dermatology, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India.

ORCID-Profile: Monisha Madhumita

Zitieren

APA

Vaidya, T., & Madhumita, M. (2025). Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis. International Journal of STD & AIDS. https://doi.org/10.1177/09564624251315781

Vancouver

Vaidya T, Madhumita M. Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis. International Journal of STD & AIDS. 2025. doi:10.1177/09564624251315781

BibTeX
@article{Vaidya2025,
  author = {Vaidya, Tanvi and Madhumita, Monisha},
  title = {Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis},
  journal = {International Journal of STD & AIDS},
  year = {2025},
  doi = {10.1177/09564624251315781}
}
Kostenlos starten →